Risk stratification for inhibitor development at first treatment for severe hemophilia A: a tool for clinical practice.
about
Prevalent inhibitors in haemophilia B subjects enrolled in the Universal Data Collection database.Current and evolving features in the clinical management of haemophiliaValidity of assessing inhibitor development in haemophilia PUPs using registry data: the EUHASS project.Characterization of a genetically engineered mouse model of hemophilia A with complete deletion of the F8 gene.Recombinant factor VIII in the management of hemophilia A: current use and future promise.Low-dose continuous infusion of factor VIII in patients with haemophilia A.Clinical advances in hemophilia management.Alloantibodies in previously untreated hemophilia A patients: the role of environmental factors.Factor VIII inhibitors in hemophilia A: rationale and latest evidenceEpidemiological aspects of inhibitor development redefine the clinical importance of inhibitors.Non-genetic risk factors and their influence on the management of patients in the clinic.Strategies for reducing inhibitor formation in severe haemophilia.The role of previously untreated patient studies in understanding the development of FVIII inhibitors.A large-scale computational study of inhibitor risk in non-severe haemophilia A.Prevention and prediction of inhibitor risk.Genetic determinants of immunogenicity to factor IX during the treatment of haemophilia B.An analysis of factors affecting the incidence of inhibitor formation in patients with congenital haemophilia in Japan.Partnering to change the world for people with haemophilia: 6(th) Haemophilia Global Summit, Prague, Czech Republic, 24-26(th) September 2015.A flow cytometry evaluation of anti-FVIII antibodies: correlation with ELISA and Bethesda assay.Improved prediction of inhibitor development in previously untreated patients with severe haemophilia A.Analyses of the FranceCoag cohort support immunogenicity differences among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A.Searching for the role of primary prophylaxis in preventing inhibitor development in hemophilia A.
P2860
Q30655343-8A2A9534-FE6D-4EBC-B487-2E1CB547715EQ33708976-A8297444-8427-4C5C-A784-292DCDE75E79Q34063824-EF317214-44B4-4E5A-948B-D7218CF882CDQ36586264-6763F66D-C289-4A93-824F-8A1977FA8AE4Q37230340-1D259925-6832-4E5C-AF2F-44462A84D4FCQ37242666-6B6FA5A9-B3A5-40EF-AD8C-CCF5ADFF9B6BQ37900933-28ADB51D-FC06-4FA3-8DAD-C124A4F4CA01Q38080144-5111D539-8C93-458C-8407-E471A2177303Q38101041-82323241-5C92-484F-8519-7E4B52D8E962Q38206855-9EA61DBD-7041-4FD4-89C3-7E001583F75DQ38308194-467FA40D-9CFB-4C63-A1B8-B48FF9ABC8FAQ38308222-C8DCE24D-2E10-4CB1-993D-54945EE91142Q38575475-30FF67D5-FE0B-403B-A090-C6506D59ECE8Q39125208-3DF7B37F-597A-4AFF-8A1E-ECFB08E21886Q39596266-714D3BF0-2777-462C-9EC7-A0B810DB3D2DQ41732261-EC13E90C-2DCD-4390-83FB-E25B25756105Q44296354-A14D61D8-B675-45C7-A93A-59F0559B009FQ45855101-F1A92D60-26FA-4BE0-8068-0B85DAEBA0D7Q45864882-BA2FB1A2-3BC6-4EB0-B18C-E6005BEBB2BBQ45871101-C53E4165-750D-4DB0-B952-C07561E62D72Q45873084-0E608724-27B0-4AEF-9C48-58147F301F17Q45880206-7168317E-577F-4481-8071-85B4086C78E4
P2860
Risk stratification for inhibitor development at first treatment for severe hemophilia A: a tool for clinical practice.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Risk stratification for inhibi ...... a tool for clinical practice.
@en
Risk stratification for inhibi ...... a tool for clinical practice.
@nl
type
label
Risk stratification for inhibi ...... a tool for clinical practice.
@en
Risk stratification for inhibi ...... a tool for clinical practice.
@nl
prefLabel
Risk stratification for inhibi ...... a tool for clinical practice.
@en
Risk stratification for inhibi ...... a tool for clinical practice.
@nl
P2093
P1476
Risk stratification for inhibi ...... a tool for clinical practice.
@en
P2093
CANAL Study Group
E Santagostino
H M van den Berg
J G van der Bom
M E Mancuso
P C ter Avest
P2860
P304
P356
10.1111/J.1538-7836.2008.03187.X
P577
2008-10-07T00:00:00Z